The Regulatory Wall: Why America Is Falling Behind in Hemp-Based Medicine — and What Must Change

In 2018, the Food and Drug Administration approved Epidiolex — a purified cannabidiol formulation derived from hemp — for the treatment of two severe, drug-resistant forms of childhood epilepsy. It was a landmark moment, the first FDA approval of a cannabis-derived pharmaceutical, and it demonstrated conclusively that hemp compounds could meet the agency's rigorous standards for safety and efficacy. Then, largely, the pipeline stalled.

Five years after that approval, no additional hemp-derived cannabinoid has cleared the FDA's full approval process. The clinical evidence base has continued to expand. Domestic hemp cultivation has grown substantially. Patient demand for evidence-based, hemp-derived therapeutics has intensified alongside the opioid crisis and a broader cultural reckoning with pharmaceutical dependency. And yet the regulatory pathway from laboratory to pharmacy shelf remains, for most hemp-derived compounds, an obstacle course designed more for obstruction than for innovation.

This is an argument for change — grounded in clinical data, comparative regulatory analysis, and a frank assessment of who bears the cost of delay.

What the Clinical Evidence Already Shows

The scientific literature on hemp-derived cannabinoids has expanded dramatically over the past decade. Cannabidiol (CBD), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV) — all compounds present in hemp at varying concentrations — have demonstrated measurable pharmacological activity across a range of conditions in peer-reviewed clinical and preclinical studies.

CBD's anticonvulsant properties, already validated through the Epidiolex trials, are the most thoroughly documented. But the evidence base extends well beyond epilepsy. A 2019 randomized controlled trial published in The Permanente Journal found that CBD supplementation significantly reduced anxiety scores and improved sleep quality in a clinical population, with a favorable side-effect profile compared to conventional anxiolytics. Research published in Neuropsychopharmacology has explored CBD's potential in mitigating opioid cravings and relapse in patients with substance use disorder — a finding with profound implications given that opioid overdose deaths surpassed 80,000 annually in the United States as recently as 2021.

CBG, sometimes described as the "mother cannabinoid" for its role as a biosynthetic precursor, has shown antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) in laboratory studies, a finding that attracted significant attention given the limited pipeline of novel antibiotics in conventional pharmaceutical development. THCV has demonstrated preliminary efficacy as an appetite suppressant and insulin sensitizer in early-phase trials, with potential applications in metabolic syndrome and type 2 diabetes management.

None of these compounds have a clear, accelerated pathway to FDA approval. And that is precisely the problem.

The Regulatory Architecture That Blocks Progress

The FDA's existing framework for evaluating new drugs was not designed with plant-derived, multi-compound botanical medicines in mind. The agency's Investigational New Drug (IND) and New Drug Application (NDA) processes impose timelines and cost structures that favor large pharmaceutical corporations with the capital to sustain decade-long development cycles. For hemp-derived compounds — many of which exist in the public domain and cannot be patented in their natural form — the commercial incentive to fund that process is structurally diminished.

The agency's 2019 guidance following the Epidiolex approval compounded the problem. The FDA took the position that because CBD had been approved as a drug, it could not simultaneously be marketed as a dietary supplement or added to food products — a ruling that created significant uncertainty for the hemp industry without providing a corresponding accelerated pathway for pharmaceutical development. The practical effect was to strand CBD in a regulatory no-man's land: too drug-like for the supplement market, but without a viable commercial pathway for most companies to pursue full drug approval.

Furthermore, the agency's continued classification of hemp-adjacent research under frameworks originally designed for Schedule I substances has created administrative friction that discourages academic researchers and smaller biotech firms from entering the development pipeline at all. While the 2018 Farm Bill's removal of hemp from Schedule I was a necessary step, the downstream regulatory infrastructure has not kept pace with the legislative intent.

Europe Is Not Waiting

The contrast with European regulatory approaches is instructive and, for American patients, deeply frustrating. The European Medicines Agency (EMA) has demonstrated a markedly more adaptive posture toward botanical cannabinoid medicines, approving Sativex — a CBD/THC oromucosal spray — for multiple sclerosis-related spasticity across numerous member states and engaging proactively with developers of novel cannabinoid formulations through its innovation office.

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has similarly established clearer guidance for cannabinoid-based medicine development, reducing the regulatory ambiguity that paralyzes American developers. Israel, which has maintained one of the world's most sophisticated medical cannabis research programs, has generated clinical trial data on cannabinoid formulations that American researchers have been unable to replicate domestically at comparable scale, largely due to regulatory and funding barriers.

The consequence is not merely symbolic. American patients seeking evidence-based cannabinoid therapies are increasingly obtaining them through informal channels — unregulated CBD products of variable quality and uncertain dosing — precisely because the regulated pharmaceutical pathway has failed to deliver alternatives. That is a public health outcome, and it is one that the FDA's current posture actively perpetuates.

The Case for Fast-Track Designation and Dedicated Pathways

The FDA already possesses the statutory authority to address this failure. The agency's Breakthrough Therapy designation, Fast Track designation, and Accelerated Approval pathway were all designed to expedite development of drugs that address serious conditions with unmet medical needs. Hemp-derived cannabinoids — particularly in the contexts of opioid use disorder, treatment-resistant anxiety, antibiotic-resistant infection, and metabolic disease — qualify on every relevant criterion.

A coalition of patient advocacy groups, hemp industry stakeholders, and academic researchers has repeatedly called on the FDA to establish a dedicated botanical cannabinoid review pathway, analogous to the agency's existing framework for botanical drug products but specifically calibrated to the regulatory history and evidentiary profile of hemp-derived compounds. To date, those calls have been met with procedural acknowledgment and no substantive action.

Congress has a role to play as well. Legislation directing the FDA to issue binding guidance on hemp-derived cannabinoid drug applications within a defined timeframe — similar to the SUPPORT for Patients and Communities Act's directives on opioid treatment — would impose the institutional urgency that the agency has thus far declined to generate internally. The Hemp Access and Consumer Safety Act, introduced in various forms over the past several congressional sessions, represents one legislative vehicle for this kind of directive authority.

The Agricultural Dimension

This is not solely a pharmaceutical policy argument. It is an agricultural one. A robust domestic market for FDA-approved hemp-derived pharmaceuticals would create stable, high-value demand for American hemp cultivation — demand that is currently suppressed by the regulatory uncertainty surrounding hemp-derived compounds. Farmers who invested in hemp production following the 2018 Farm Bill have faced volatile and often inadequate markets in part because the most lucrative downstream application — pharmaceutical-grade cannabinoid production — remains inaccessible without a functioning regulatory pathway.

Establishing that pathway would align public health objectives with agricultural development goals, creating the kind of vertically integrated domestic supply chain that reduces import dependence and supports rural economic recovery. It would position American hemp farmers as suppliers to a regulated, growing pharmaceutical market rather than to an unregulated supplement market characterized by chronic oversupply and price compression.

The Cost of Waiting

Every year that the FDA delays meaningful regulatory reform is a year in which patients with treatment-resistant conditions rely on inadequately studied, inconsistently produced hemp products rather than rigorously tested pharmaceuticals. It is a year in which European and Israeli researchers publish clinical findings that American scientists were structurally prevented from generating. And it is a year in which the domestic hemp industry — a sector with genuine potential to contribute to both agricultural sustainability and pharmaceutical innovation — operates without the regulatory foundation it needs to reach its full productive capacity.

The science is not waiting. The patients are not waiting. The only institution that appears content to wait is the one with the authority to act.